Page 12 - பல்கலைக்கழகம் ஆஃப் ஹைதராபாத் ஊஓ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VINS Bioproducts gets DCGI nod to commence clinical trials for VINCOV-19 ANI | Updated: Apr 26, 2021 14:59 IST Hyderabad (Telangana) [India], April 26 (ANI): VINS Bioproducts on Monday received approval from the Drugs Controller General of India (DCGI) to commence the clinical trials for VINCOV-19, an antidote, and a cure against COVID-19, the Hyderabad based immunological company said. In a statement, VINS Bioproducts said that VINCOV-19, developed by VINS Bioproducts in collaboration with Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), as an antidote and a cure, is a significant step in the fight against coronavirus. The clinical trials of VINCOV-19 will involve over 300 subjects spread across the country. The safety and efficacy of the antibodies will be examined in a group of around 300 patients, with COVID-19, informed the statement.

Andhra pradeshUniversity of hyderabad uoCentre for cellularIndian council of medical researchUniversity of hyderabadDrugs controller generalMolecular biologySiddharth dagaChief executive officerIndian councilMedical researchClinical trialsVincov 19Covid vaccineVins bioproductsCovid vaccination